2024-13-011 + 2019-06-006 - Hepta4IBD - Heptammune: a first-in-class biologic immunomodulator against autoimmune inflammatory bowel disease

Heptammune, a first-in-class biologic immunomodulator against Inflammatory Bowel Disease

2021-08-002 + 2019-06-002 + 2019-05-005 - MetalA-MDR 05 - New metal-antibiotics against multidrug-resistant bacteria

Develop an innovative metalloantibiotic based on gold (III) to treat all types of infections caused by MDR bacteria

2019-06-015 - miRFec - Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer

The miRFec test –a Gradient Boosting Machine-generated algorithm that includes two fecal miRNAs (miR-421 and miR-27a-3p) and fecal hemoglobin concentration, along with age and gender– is more effective and cost-effective than FIT for the identification of patients with advanced colorectal neoplasm (i.e. CRC, AA or advanced serrated lesions [ASL]) among individuals participating in CRC screening programs.

2019-06-012 - AFIB - Diagnosis markers for atrial fibrillation

Diagnosis markers for atrial fibrillation

2019-06-005 - CollyiruNP - Eye drops enriched with antioxidant nanoparticles for the treatment of age-related macular degeneration

Eye drops enriched with antioxidant nanoparticles for the treatment of age-related macular degeneration.

2019-06-013 - AQUATRAFFIC 02 - Protection of a novel protein trafficking domain for membrane channels

Cryopreservation of oocytes and embryos with high yolk content (fish, amphibians, reptiles, birds) has never been achieved. A novel protein trafficking domain has been discovered that can be used to specifically insert channels in the YP membrane, thus allowing water efflux and the incorporation of cryoprotective solutes. This domain is present in channels involved in fluid secretion in human pancreatic acinar cells.

2019-06-018 - Biomarker-CDx - Novel biomarker for precision medicine

We have discovered a new biomarker useful to identify cancer patients with a TGFβ-activated microenvironment in colorectal cancer (CRC) and other tumor types. This biomarker can be used for personalized medicine purposes as follows: i. by selecting those patients able to respond to TGFβ signaling pathway inhibitors; ii. by selecting patients non-responders to immune checkpoint inhibitors (i.e anti-PDL1, anti PD1), due to the presence of a modified microenvironment by high TGFβ levels. The latter set of patients may be selected to prescribe therapy with immune checkpoint inhibitors such as anti-PDL1 and anti-PD1 in combination with TGFβ signaling pathway inhibitors. The biomarker can be also used as a prognostic method to better classify the aggressiveness of CRC, particularly according to the recently proposed CMS classification (Consensus Molecular Subtype, Guinney et al., Nature Medicine, 2015), risk of recurrence and metastasis. Thus, the biomarker covers a high unmet medical need which is the devise of better classifiers of cancer stage and aggressiveness.

2019-06-016 + 2019-05-004 - PHOTO-RX 03 - Photoreactors for high-througput experimentation

Design and construction of very efficient specialized equipment to perform light irradiation

2021-08-012 + 2019-06-008 - ONCOBOTS - The use of self-propelled urease nanoparticles for the treatment of non-invasive bladder cancer

ONCOBOTS is a patented technology based on enzyme-powered nanomotors, which are capable to navigate in fluids due to the biocatalytic decomposition of fuel contained in body fluids. ONCOBOTS core can be loaded with anticancer drugs and their surface can also include additional moieties, such as antibodies for cancer targeting, PEG for immune system camouflaging, or markers for fluorescence detection.

2019-06-011 - AONs2CureCancer - Splicing-modifying antisense oligonucleotides to treat lung cancer

We are developing an innovative therapy based on the use of Antisense Oligonucleotides (AONs) that regulate alternative splicing (AS) of the gene NUMB. AS is the process that allows the synthesis of different protein variants from a single gene by differential selection of exonic sequences. In this process, particular exons of a gene may be included within or excluded from the final processed mRNA produced from that gene. We previously characterized the RNA binding protein RBM10 as a regulator of NUMB exon 9 AS and showed that mutations in RBM10 disrupt RBM10-mediated AS of NUMB exon 9. This leads to higher levels of NUMB exon 9 inclusion and higher cell proliferation lung adenocarcinoma (LUAD) colony formation assays and in mouse tumour xenografts. Indeed, RBM10 is among the most frequently mutated genes in LUAD and increased inclusion of NUMB exon 9 is observed in the vast majority of LUAD tumours. The degree of exon 9 inclusion correlates with worse disease prognosis. Using our proprietary AONs, we have demonstrated that our novel therapy corrects NUMB exon 9 pathological inclusión caused by RBM10 mutations in LUAD, significantly inhibiting cancer cell proliferation, reducing tumour growth in four different mouse models of LUAD, including two patient-derived xenograft models in which we observe in addition an increased survival. We are currently finalizing the optimization of the AONs and administration route. After that, we are planning to start preclinical regulatory studies with our optimized preclinical candidate.